Dianthus Therapeutics (DNTH) Net Equity Issued and Repurchased (2017 - 2025)

Dianthus Therapeutics' (DNTH) quarterly Net Equity Issued and Repurchased came in at $187000.0 in Q3 2025, up 44.96% quarter-over-quarter from $129000.0 in Q1 2025.

Dianthus Therapeutics (DNTH) Net Equity Issued and Repurchased (2017 - 2025) Analysis & Trends

Dianthus Therapeutics' Net Equity Issued and Repurchased history runs 5 years deep, the most recent figure standing at $187000.0 for Q3 2025.

  • On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to $187000.0 in Q3 2025; TTM through Sep 2025 was $39.5 million, a N/A change from a year earlier, with the FY2024 full-year figure at $39.2 million, changed N/A from the prior year.
  • Net Equity Issued and Repurchased climbed to $187000.0 in Q3 2025 per DNTH's latest filing, from $129000.0 in the prior quarter.
  • Across five years, Net Equity Issued and Repurchased topped out at $39.2 million in Q4 2024 and bottomed at $129000.0 in Q1 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Equity Issued and Repurchased (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn -
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 163.10 Mn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - 141.90 Mn
10 Dianthus Therapeutics 3.37 Bn 2.97 Bn - -

Historic Data

Download Data
DateValue
Sep 30, 2025 187,000.00
Sep 30, 2025 187,000.00
Mar 31, 2025 129,000.00
Mar 31, 2025 129,000.00
Dec 31, 2024 39.20 Mn
Dec 31, 2024 39.20 Mn
Jun 30, 2020 64.60 Mn
Jun 30, 2020 64.60 Mn
Sep 30, 2018 40.70 Mn
Sep 30, 2018 40.70 Mn
Sep 30, 2017 2.00 Mn
Sep 30, 2017 2.00 Mn
Jun 30, 2017 54.30 Mn
Jun 30, 2017 54.30 Mn